SEC Form 4 · accession 0001209191-18-045024
Cue Biopharma, Inc. · CUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bethany Mancilla
Officer — SVP and Chief Business Officer
Period of report
Aug 1, 2018
Accepted (ET)
Aug 2, 2018 · 5:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645460
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.54 | Aug 1, 2018 | A | 250,000 | A | — | Aug 1, 2025 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1This stock option grant becomes exercisable in eight equal semi-annual installments beginning February 1, 2019.